Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$88.8MCash, Jun 2026
21moCash Runway (est.)
+39%Share Count, 1 Year
Follow IRD by emailGet an email when IRD pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about IRD, unsubscribe in one click. Privacy
📣 What IRD Says Is Next
Q4 2026 · “Based on the safety profile and positive proof-of-concept findings from Cohort 1, the Company has advanced to the higher-dose Cohort 2, evaluating OPGx-BEST1 at 4.5 x 10⁹ vg/eye, with dosing expected to be completed in Q4 2026 and topline three-month data expected in Q2 2027.”
Company press release, Sep 9, 2026 · SEC filing
in 2027 · “The Company expects to begin planning for the Phase 3 trial immediately, with participant dosing expected to begin in 2027.”
Company press release, Sep 9, 2026 · SEC filing
early 2027 · “The Company also aligned with the FDA on Phase 3 and commercial manufacturing requirements, which it expects to complete in early 2027.”
Company press release, Sep 9, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
💰 Cash Runway & Dilution Risk
IRD reported $88.8M in cash and short-term investments (as of Jun 30, 2026) and used about $12.4M/quarter in operations, an estimated runway of 21.4 months at that rate (BioRadar estimate, not company guidance).
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IRD and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.